Biotech entity
Crinetics Pharmaceuticals is most often covered alongside Baldwin, which appears in 1 of these 2 stories. The 155-day window averages about 0.1 stories each week. They are less corroborated than the beat average, carrying 2.5 original sources each against 3.8 for the same window.
Last mentioned: Jul 31, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Crinetics Pharmaceuticals is most often covered alongside Baldwin, which appears in 1 of these 2 stories. The 155-day window averages about 0.1 stories each week. They are less corroborated than the beat average, carrying 2.5 original sources each against 3.8 for the same window. Coverage clusters in acquisition, which accounts for 1 of those 2, with the remainder spread across 1 other category. At 5.5, the average consequence score sits below the same-window beat average of 6.3. This profile follows 2 Biotech stories mentioning Crinetics Pharmaceuticals across the period from February 27, 2026 to July 31, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 522 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Crinetics Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Vertex announces $10 billion acquisition of Crinetics
Vertex Pharmaceuticals agrees to buy Crinetics Pharmaceuticals for $10 billion in cash, gaining a pipeline of endocrine therapies; the deal has not yet closed.
NDA Submission
Planned submission of paltusotine New Drug Application to the FDA.
Phase 3 Initiation
Anticipated start of Phase 3 trials for atumelnant in CAH and Cushing's disease.
Earnings Call
Management confirms commercial readiness and pipeline acceleration.
PATHFNDR-2 Success
Completion of Phase 3 trial for paltusotine in acromegaly with positive results.
Vertex's $10B buyout of Crinetics highlights the frenzied demand for metabolic pipelines. Viking Therapeutics, with a Phase 3 obesity asset and an oral candidate nearing late-stage trials, now looks like the most logical next takeover target in the rapidly expanding $190B weight-loss market.
Source: Prosper Junior Bakiny (us) · fool.com
Crinetics Pharmaceuticals reported strong Q4 2025 results, highlighting the successful completion of Phase 3 trials for paltusotine and preparations for a 2026 New Drug Application (NDA). The company is positioning itself for a major commercial pivot in endocrine disorders, supported by a robust balance sheet and positive data for its second lead candidate, atumelnant.
Crinetics Pharmaceuticals is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
